Association of fibronectin 1 deregulation with tyrosine kinase inhibitor resistance in chronic myeloid leukemia

IntroductionTherapy of chronic myeloid leukemia (CML) with tyrosine kinase inhibitors (TKIs) targeting the BCR::ABL1 kinase has become a paradigm for precision oncology. Despite the tremendous success of this strategy, with an overall long-term survival rate of 83%, approximately 25% of CML patients...

وصف كامل

التفاصيل البيبلوغرافية

المؤلفون الرئيسيون:	Lina Tiedemann, Sivahari Prasad Gorantla, Philine Ahlf, Lucie Sophie Schmidt, Christiane Pott, Merit Litterst, Vicki Waetzig, Inga Nagel, Johanna Ruemenapp, Nikolas von Bubnoff, Ingolf Cascorbi, Meike Kaehler
التنسيق:	Artigo
اللغة:	Inglês
منشور في:	Frontiers Media S.A. 2025-12-01
سلاسل:	Frontiers in Cell and Developmental Biology
الموضوعات:	chronic myeloid leukemia drug resistance fibronectin 1 imatinib tyrosine kinase inhibitor
الوصول للمادة أونلاين:	https://www.frontiersin.org/articles/10.3389/fcell.2025.1725857/full
الوسوم:	إضافة وسم لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!